Chronic liver diseases such as nonalcoholic fatty liver disease (NAFLD) or viral hepatitis are
characterized by persistent inflammation and subsequent liver fibrosis. Liver fibrosis critically …

Steady progress over four decades toward understanding the pathogenesis and clinical
consequences of hepatic fibrosis has led to the expectation of effective antifibrotic drugs, yet …

The first edition of the clinical practice guidelines for liver cirrhosis was published in 2010,
and the second edition was published in 2015 by the Japanese Society of Gastroenterology …

Importance Cirrhosis affects approximately 2.2 million adults in the US. From 2010 to 2021,
the annual age-adjusted mortality of cirrhosis increased from 14.9 per 100 000 to 21.9 per …

HCC is one of the most common cancers worldwide, and the third leading cause of cancer‐
related death globally. HCC comprises nearly 90% of all cases of primary liver cancer …

Liver fibrosis due to viral or metabolic chronic liver diseases is a major challenge of global
health. Correlating with liver disease progression, fibrosis is a key factor for liver disease …

Background Non-alcoholic steatohepatitis (NASH) is a common type of chronic liver disease
that can lead to cirrhosis. Obeticholic acid, a farnesoid X receptor agonist, has been shown …

Liver fibrosis is an advanced liver disease condition, which could progress to cirrhosis and
hepatocellular carcinoma. To date, there is no direct approved antifibrotic therapy, and …

Fibrosis, defined by the excess deposition of structural and matricellular proteins in the
extracellular space, underlies tissue dysfunction in multiple chronic diseases. Approved …

Background and Aims Studies are needed to determine the long-term effects of bariatric
surgery for patients with nonalcoholic steatohepatitis (NASH). We evaluated sequential liver …